Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 66
Filter
1.
Article in Spanish | LILACS, BNUY, UY-BNMED | ID: biblio-1358322

ABSTRACT

Se describe los casos de tres pacientes a quien se les realiza diagnóstico de colestasis intrahepática del embarazo (CIE) de aparición temprana. En dos de ellos el diagnóstico se relacionó con infección por el virus de la hepatitis C (VHC). Reconocer que esta enfermedad puede presentarse de manera temprana en el embarazo y su relación con la infección por el VHC es fundamental para hacer un diagnóstico oportuno de ambas enfermedades y tomar las conductas terapéuticas adecuadas, mejorando así el pronóstico materno y fetal.


It is of great importance to acknowledge that this disease can occur early in pregnancy and that its relationship with HCV infection is a key point for a prompt diagnosis, allowing taking timely appropriate therapeutic decisions, aimed at improving the fetal prognosis.


Descrevemos os casos de três pacientes com diagnóstico de colestase intra-hepática da gravidez de início precoce. Em dois deles o diagnóstico estava relacionado à infecção pelo vírus da hepatite C (VHC). Reconhecer que esta doença pode se manifestar precocemente na gravidez e sua relação com a infecção pelo VHC é fundamental para fazer um diagnóstico oportuno de ambas as doenças e assumir condutas terapêuticas adequadas, melhorando assim o prognóstico materno e fetal.


Subject(s)
Humans , Female , Pregnancy , Adult , Pregnancy Complications, Infectious/diagnosis , Pruritus , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/etiology , Hepatitis C/complications , Pregnancy Trimester, Second , Pregnancy Trimester, First , Ursodeoxycholic Acid/therapeutic use , Chlorpheniramine/therapeutic use , Cholestasis, Intrahepatic/drug therapy , Hepatitis C/diagnosis , Early Diagnosis
2.
Brasília; s.n; 11 ago. 2020.
Non-conventional in Portuguese | PIE, LILACS, BRISA, PIE | ID: biblio-1117979

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 14 artigos e 5 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Ribavirin/therapeutic use , Technology Assessment, Biomedical , Ursodeoxycholic Acid/therapeutic use , Immunoglobulins/therapeutic use , Prednisolone/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Chloroquine/therapeutic use , Cross-Sectional Studies , Cohort Studies , Interferon-alpha/therapeutic use , Tacrolimus/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Azithromycin/therapeutic use , Ritonavir/therapeutic use , Antibodies, Neutralizing/therapeutic use , Mesenchymal Stem Cells , Lopinavir/therapeutic use , Folic Acid/therapeutic use , Meropenem/therapeutic use , Hydroxychloroquine/therapeutic use , Antibodies, Monoclonal/therapeutic use , Mycophenolic Acid/therapeutic use
3.
Prensa méd. argent ; 105(1): 34-40, mar 2019. tab, graf
Article in English | LILACS, BINACIS | ID: biblio-1026338

ABSTRACT

Being the main treatment for cholelithiasis, laparoscopic cholecystectomy does not always solve the problem. It often entails postcholecystectomy syndrome (PCS). Oral medication to dissolve gallstones with bile acids is alternative therapy for some patients. However, lack of efficacy and limited medical indications make it necessary to apply combination treatment tactics. This study was conducted to investigate the dissolution of gallstones during the combined effects of ursodeoxycholic acid (UDCA) and rosuvastatin as well as to assess the results of eradication therapy in the presence of H. pylory as a measure to prevent cholelithiasis in the course of treatment.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Ursodeoxycholic Acid/therapeutic use , Cholelithiasis/prevention & control , Cholelithiasis/drug therapy , Administration, Oral , Helicobacter pylori , Drug Therapy, Combination/trends , Disease Eradication , Rosuvastatin Calcium/therapeutic use
4.
Acta cir. bras ; 34(1): e20190010000009, 2019. tab, graf
Article in English | LILACS | ID: biblio-983686

ABSTRACT

Abstract Purpose: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. Methods: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA, starting 30 days after the surgery, at a dose of 150 mg twice daily (300 mg/day) over a period of 5 consecutive months (GROUP A), and 68 were control patients (GROUP B). The patients were followed-up, and ultrasonography was performed to determine the presence of gallstones at various times during follow-up. Demographic, anthropometric and comorbid indicators were obtained. The data were subjected to normality tests and evaluated using appropriate tests. Results: Patients did not differ in their baseline characteristics. Of the 69 patients who used UDCA, only one patient developed cholelithiasis (1%), whereas 18 controls (26%) formed gallstones (OR = 24.4, p <0.001). Also, other factors were found not to influence the formation of calculi, such as pre-operative or postoperative hepatic steatosis or diabetes (p = 0.759, 0.468, 0.956). Conclusion: The results demonstrated that patients who did not use UDCA showed a 24.4-fold greater probability of developing cholelithiasis.


Subject(s)
Humans , Male , Female , Adult , Postoperative Complications/prevention & control , Ursodeoxycholic Acid/therapeutic use , Obesity, Morbid/surgery , Cholagogues and Choleretics/therapeutic use , Gastric Bypass/adverse effects , Gallstones/prevention & control , Postoperative Complications/etiology , Postoperative Complications/drug therapy , Postoperative Period , Stomach/surgery , Gallstones/etiology , Gallstones/drug therapy , Comorbidity , Anthropometry , Prospective Studies
5.
Ann. hepatol ; 16(3): 430-435, May.-Jun. 2017. tab, graf
Article in English | LILACS | ID: biblio-887255

ABSTRACT

ABSTRACT Introduction. There is little information on survival rates of patients with primary biliary cholangtis (PBC) in developing countries. This is particularly true in Latin America, where the number of liver transplants performed remains extremely low for patients with advanced liver disease who fulfill criteria for liver transplantation. The goal of this study was to compare survival rate of patients with PBC in developing countries who were treated with ursodeoxycholic acid (UDCA) versus survival of patients who received other treatments (OT) without UDCA, prescribed before the UDCA era. Material and methods. A retrospective study was performed, including records of 78 patients with PBC in the liver unit in a third level referral hospital in Mexico City. Patients were followed for five years from initial diagnosis until death related to liver disease or to the end of the study. Patients received UDCA (15 mg/kg/per day) (n = 41) or OT (n = 37) before introduction of UDCA in Mexico. Results. Response to treatment was higher in the group that received UDCA. In the five years of follow-up, survival rates were significantly higher in the UDCA group than in the OT group. The hazard ratio of death was higher in the OT group vs. UDCA group, HR 8.78 (95% Cl, 2.52-30.61); Mayo Risk Score and gender were independently associated with the risk of death. Conclusions. The study confirms that the use of UDCA in countries with a limited liver transplant program increases survival in comparison to other treatments used before the introduction of UDCA.(AU)


Subject(s)
Humans , Ursodeoxycholic Acid/therapeutic use , Liver Transplantation/adverse effects , Liver Cirrhosis, Biliary/physiopathology , Survival Rate , Retrospective Studies , Latin America
6.
Gastroenterol. latinoam ; 27(supl.1): S60-S63, 2016. tab
Article in Spanish | LILACS | ID: biblio-907656

ABSTRACT

The introduction of ursodeoxycholic acid (UDCA) in the treatment of patients with cholestasis enabled remarkable progress and improvements in hepatic inflammatory activity, progression to cirrhosis and quality of life. However, the benefits of UDCA are particularly evident in patients with primary biliary cirrhosis and also 30 percent of patients have sub optimal response. For this reason, in order to improve the number of people with complete responses to therapy, new pharmacological alternatives have been investigated to add to UDCA treatment. This review aims to show potential new therapies against cholestasis that have been investigated by systematizing them depending on the receptor or target on which they act. Finally, a special reference will be made in relation to the treatment of pruritus associated with cholestasis.


La introducción del ácido ursodeoxicólico (AUDC) en el tratamiento de los pacientes con colestasia permitió notables avances con mejoras en la actividad inflamatoria hepática, progresión hacia la cirrosis y calidad de vida. Sin embargo, los beneficios de AUDC se aprecian especialmente en pacientes con cirrosis biliar primaria y además, 30 por ciento de los pacientes tiene una respuesta sub óptima. Por esta razón, con la finalidad de mejorar el número de personas con respuestas completas a la terapia, se han investigado nuevas alternativas farmacológicas para adicionar al tratamiento con AUDC. La presente revisión pretende mostrar las nuevas posibles terapias contra la colestasia estudiadas sistematizándolas según el tipo de receptor o diana sobre el que actúan. Finalmente se hará referencia especial en relación al tratamiento del prurito asociado a la colestasia.


Subject(s)
Humans , Cholestasis/complications , Cholestasis/drug therapy , Receptors, G-Protein-Coupled/therapeutic use , Ursodeoxycholic Acid/therapeutic use , Vitamin D/therapeutic use , Budesonide/therapeutic use , Pruritus/drug therapy , Pruritus/etiology
7.
Article in English | WPRIM | ID: wpr-128617

ABSTRACT

BACKGROUND/AIMS: Overlap syndrome of autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) (AIH-PBC overlap syndrome) is a rare disease that has not been clearly characterized in Korean patients. This study investigated the clinical features of AIH-PBC overlap syndrome compared with those of AIH and PBC alone. METHODS: This retrospective cohort study included 158 consecutive patients who were diagnosed as AIH (n=61), PBC (n=81), or AIH-PBC overlap syndrome (n=9) based on the Paris and the International Autoimmune Hepatitis Group (IAIHG) criteria from 2001 to 2011 in Korea. We compared the clinical features of these three groups retrospectively, including their biochemical characteristics, treatments, responses, and clinical outcomes. RESULTS: The AIH-PBC overlap syndrome patients exhibited biochemical characteristics of both AIH and PBC, and showed a similar response to ursodeoxycholic acid (UDCA) monotherapy as for the PBC patients. However, the response of AIH-PBC overlap syndrome patients to UDCA and steroid combination therapy was worse than the response of AIH patients to steroid-based therapy (P=0.024). Liver cirrhosis developed more rapidly in AIH-PBC overlap syndrome patients than in AIH patients group (P=0.013), but there was no difference between AIH-PBC overlap syndrome patients and PBC patients. The rates of developing hepatic decompensation did not differ significantly between the groups. CONCLUSIONS: The AIH-PBC overlap syndrome patients exhibited a worse response to UDCA and steroid combination therapy and a faster cirrhotic progression compared with AIH patients.


Subject(s)
Adult , Aged , Cohort Studies , Drug Therapy, Combination , Female , Hepatitis, Autoimmune/complications , Humans , Liver/metabolism , Liver Cirrhosis, Biliary/complications , Male , Middle Aged , Republic of Korea , Retrospective Studies , Steroids/therapeutic use , Treatment Outcome , Ursodeoxycholic Acid/therapeutic use
8.
Rev. fac. cienc. méd. (Impr.) ; 11(2): 40-44, jul.-dic. 2014. ilus
Article in Spanish | LILACS | ID: biblio-1764

ABSTRACT

La cirrosis biliar primaria es una enfermedad hepática colestásica crónica, lentamente progresiva, caracterizada por la destrucción no supurativa de la vía biliar interlobulillar y septal. Se presenta principalmente en mujeres de edad media, con incidencia de 0.7-49 casos por millón de habitantes. El propósito de estudiar este caso es describir una enfermedad de difícil diagnóstico, dado que las manifestaciones clínicas pueden orientar a una variedad de posibilidades; sumado a esto la baja incidencia y bajo índice de sospecha que dificulta aún más el hallazgo. Caso clínico: se presenta caso de paciente femenina de 24 años, que llegó a la emergencia del Hospital Escuela Universitario por cuadro de diarrea de un mes de evolución, aproximadamente 3-4 episodios por día, de consistencia blanda, color amarillento, sin exacerbantes; prurito generalizado sin predominio de horario. Al examen físico tinte ictérico en piel y mucosas, abdomen simétrico, sin presencia de cicatrices, dolor a la palpación profunda en hipocondrio derecho, hígado palpable 2 cm debajo del reborde costal.El diagnóstico se realizó mediante la detección de anticuerpos antimitocondriales en suero y la realización de una biopsia hepática. Después de iniciado el tratamiento, comenzó a disminuir el tinte ictérico y los niveles de bilirrubinas, la paciente fue dada de alta y continuó el manejo. Conclusión: el tratamiento temprano con ácido ursodesoxicólico, puede detener la progresión de la enfermedad y mejorar el pronóstico. Para los pacientes que muestran respuesta insuficiente, la terapia combinada con bezafibrato usualmente es efectiva...(AU)


Subject(s)
Humans , Female , Adult , Biopsy , Hepatitis , Liver Cirrhosis, Biliary , Liver Cirrhosis, Biliary/diagnosis , Ursodeoxycholic Acid/therapeutic use
9.
Femina ; 42(1): 39-42, jan-fev. 2014.
Article in Portuguese | LILACS | ID: lil-749140

ABSTRACT

A colestase intra-hepática da gravidez caracteriza-se pelo aparecimento de prurido generalizado no segundo ou terceiro trimestre gestacional e alterações dos ácidos biliares e das enzimas hepáticas. Sua etiologia não é totalmente conhecida, mas pode comprometer o prognóstico perinatal. Esta revisão teve como objetivo avaliar as principais opções terapêuticas desta intercorrência, com base nas melhores evidências científicas disponíveis. O tratamento dessa colestase permanece polêmico. Entre as opções medicamentosas, o uso do ácido ursodesoxicólico parece ser a melhor, favorecendo melhoria do prognóstico perinatal.(AU)


Intrahepatic cholestasis of pregnancy is characterized by the appearance of generalized pruritus in the second or third trimester with changes in bile acids and liver enzymes. Its etiology is not fully known but may impair the perinatal outcome. This review aimed to evaluate the main therapeutic options for this complication based on the best available scientific evidence. The treatment of this cholestasis remains controversial. Among the drug options the use of ursodeoxycholic acid appears to be the best choice to improve the perinatal outcome.(AU)


Subject(s)
Humans , Female , Pregnancy , Pregnancy Complications/prevention & control , Ursodeoxycholic Acid/therapeutic use , Cholestasis, Intrahepatic/drug therapy , Prognosis , Databases, Bibliographic , Pregnancy, High-Risk , Liver Function Tests
10.
Article in Korean | WPRIM | ID: wpr-113903

ABSTRACT

BACKGROUND/AIMS: Chronic hepatocellular damage is closely associated with hepatic fibrosis and fatal complication in most liver diseases. The aim of this study is to compare the efficacy and safety of biphenyl dimethyl dicarboxylate (DDB) and ursodeoxycholic acid (UDCA) in patients with abnormal ALT. METHODS: One-hundred thirty-five patients with elevated ALT were randomized to receive either 750 mg/day of DDB or 300 mg/day of UDCA for 24 weeks in 4 referral hospitals. Ninety-three (69%) patients had non-alcoholic steatohepatitits, 27 (20%) had alcoholic hepatitis, and 15 (11%) had chronic hepatitis. The primary end point was the rate of ALT normalization at week 24. The secondary endpoints were changes in AST, liver stiffness, and the incidence of adverse events. RESULTS: A total of 101 patients completed 24 weeks of therapy. ALT normalization at week 24 was observed in 44 (80.0%) patients in DDB group and 16 (34.8%) in UDCA group (p<0.001). Higher mean reduction of ALT levels from baseline to 24 weeks was seen in DDB group compared with UDCA group (-70.0% vs. -35.9%, p<0.001). Normalization of AST level (p=0.53) and change in the liver stiffness (p=0.703) were not significantly different between the two groups. Severe adverse drug reaction occurred in 1 patient in DDB group but the subject continued therapy during the study period. CONCLUSIONS: DDB was not inferior to UDCA for normalizing ALT level. Furthermore it was safe and well tolerated by patients with abnormal ALT.


Subject(s)
Adolescent , Adult , Aged , Alanine Transaminase/blood , Cholagogues and Choleretics/therapeutic use , Dioxoles/therapeutic use , Double-Blind Method , Drug Administration Schedule , Female , Follow-Up Studies , Hepatitis, Alcoholic/drug therapy , Hepatitis, Chronic/drug therapy , Humans , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/drug therapy , Tertiary Care Centers , Treatment Outcome , Ursodeoxycholic Acid/therapeutic use , Young Adult
11.
Article in Korean | WPRIM | ID: wpr-155062

ABSTRACT

The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease. Surveillance colonoscopy has not been shown to prolong survival and rates of interval cancer are reported to be high. Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents such as the 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents. This review focuses on various chemopreventive agents that have been clearly shown to reduce the risk of colorectal adenoma and cancer in the patients with inflammatory bowel disease.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Chemoprevention , Colorectal Neoplasms/complications , Folic Acid/therapeutic use , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/complications , Mesalamine/therapeutic use , Ursodeoxycholic Acid/therapeutic use
12.
Gastroenterol. latinoam ; 24(4): 185-190, 2013.
Article in Spanish | LILACS | ID: lil-765137

ABSTRACT

cancer in patients with primary sclerosing cholangitis/ulcerative colitis? Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of intra-and extrahepatic bile ducts. About 70 percent of patients with CEP have idiopathic ulcerative colitis (IUC). PSC is considered a premalignant condition with an increased risk of colorectal cancer (CC). Individuals with PSC and IUC have higher risk of developing CC than IUC patients. There are different positions between American and European experts in the fields of hepatology and inflammatory bowel disease regarding the use of ursodeoxycholic acid (UDCA) in PSC and IUC as a chemo preventive. Studies have shown mixed results about the use of UDCA in preventing CC. The following is an update on the role of UDCA as a chemo preventive in this group of patients.


La colangitis esclerosante primaria (CEP) es una enfermedad crónica hepática colestásica caracterizada por inflamación y fibrosis de ductos biliares intra y extrahepáticos. Alrededor de 70 por ciento de los pacientes con CEP presenta colitis ulcerosa idiopática (CUI). La CEP es considerada una condición premaligna con un incremento del riesgo de cáncer colorrectal (CCR). Individuos con CEP más CUI tienen mayor riesgo de desarrollar CCR que pacientes con sólo CUI. Existen distintas posturas a nivel mundial entre expertos americanos y europeos tanto en el área de la hepatología como en el área de las EII (enfermedades inflamatorias intestinales) frente al uso de ácido ursodeoxicólico (AUDOC) en CEP y CUI como quimioprotector. Estudios han mostrado resultados contradictorios para el uso de AUDOC en la prevención de CCR. Se expone una revisión actualizada sobre el rol de AUDOC como quimioprotector en este grupo de pacientes.


Subject(s)
Humans , Ursodeoxycholic Acid/therapeutic use , Cholangitis, Sclerosing/pathology , Colorectal Neoplasms/prevention & control , Ursodeoxycholic Acid/adverse effects , Colitis, Ulcerative/pathology
13.
GEN ; 66(4): 224-227, dic. 2012. ilus, graf, mapas, tab
Article in Spanish | LILACS | ID: lil-676448

ABSTRACT

Introducción: La enfermedad hepática grasa no alcohólica (EHGNA), tiene una prevalencia del 10 % al 24 % en la población general, con una historia natural poco conocida para poder establecer sus opciones terapéuticas. El ácido ursodosoxicólico (AUDC) es una droga utilizada en enfermedades hepáticas colestásicas, la cual tiene un efecto citoprotector en la EHGNA, en donde el estrés oxidativo es uno de los mecanismos fisiopatológicos. Objetivos: evaluar la eficacia del AUDC para mejorar los valores de aminotransferasas (ALT) en un tiempo determinado. Pacientes y métodos: se realizó un estudio prospectivo, experimental, incluyendo aquellos sujetos con aumento de ALT que acudieron a la consulta de centro privado entre enero 2009 - diciembre 2011, se les indicó AUDC a 13 mg/Kg/día por 12 semanas. Para el análisis estadístico se utilizó la prueba de Kolmogorov- Smirnov con un nivel de significancia del 99 % y Chi2 con un nivel de significancia del 95 %. Resultados: del total de los casos n=53, 55 % (n=29) perteneció al sexo femenino con una media de edad de 47,1 años (DS ±13,7 años). Al comparar los promedios de ALT antes y después del tratamiento del total de la muestra, se obtuvo una media 122,3 U/L y 64,7 U/L respectivamente, siendo estas diferencias significativas (p<0,001). Al comparar según sexo, hubo diferencias significativas tanto para el femenino en los promedios ALT antes y después del tratamiento: 110,9 U/L y 53,13 U/L, como en el sexo masculino 136 U/L y 78,7 U/L respectivamente, p<0,001. Existe una relación entre las variables y tiempo de tratamiento, observándose diferencias significativas al comparar los valores de ALT a las 4,8 y 12 semanas con 34,8 %, 30 % y 80 % respectivamente, siendo mayor a las 12 semanas, p<0,05. Conclusión: en nuestro estudio se pudo determinar que el AUDC en un tiempo establecido, mostro ser eficaz para la reducción de los niveles de ALT.


The history natural is poorly unknown for focused therapeutic options. Ursodeoxycholic Acid (UDCA) has long been used in the chronic cholestatic liver diseases, in NALFD believed to have cytoprotective properties and may help to reduce oxidative stress. Objetive: to know the efficacy of UDCA for improvement the serum aminotransferase levels (ALT). Patients and Methods: a prospective, experimental study was performed between january 2009 and december 2011 all patients with elevated ALT were included received UDCA 13 mg/kg/daily for 12 weeks. Analyses were conducted using Kolmogorov-Smirnov and chi-squared test with p<0,001 and p<0,05 was considered as the level of significance respectively. Results: a total of 53 patients, 55 % were female with a mean of 47,1 years old (DS±13,7 years). To compare the mean of ALT among the patients underwent starting treatment before and after was 122,3 U/L y 64,7 U/L respectively and statistically significant p<0,001 and the mean of ALT female gender was rate of response showed difference in patients 110,9 U/L y 53,13 U/L and male gender was 136 U/L y 78,7 U/L before and after UDCA was statistically significant p<0,001. Rate of response did differ in patients treated with UDCA 4, 8 and 12 weeks was 34,8 %, 30 % y 80 % respectively being statistically significant p<0,05 % at 12 weeks. Conclusion: at the present study we determined that UDCA was effective, in a given time, for improvement the serum aminotransferase levels.


Subject(s)
Humans , Male , Adolescent , Adult , Female , Young Adult , Ursodeoxycholic Acid/administration & dosage , Ursodeoxycholic Acid/therapeutic use , Chemical and Drug Induced Liver Injury, Chronic/pathology , Obesity/complications , Metabolic Syndrome/complications
14.
Article in Korean | WPRIM | ID: wpr-59916

ABSTRACT

Obesity is an important health problem in the world and related to many critical diseases, such as diabetes, cardiovascular disease, and metabolic syndrome. Obesity leads to fat infiltration of multiple organs and infiltrated adipose tissue produces many cytokines resulting in the dysfunction of organs such as the gallbladder. In the biliary diseases, obesity and overweight have been known as a major risk factor for gallstones. According to current studies, obesity, insulin resistance, hyperinsulinemia, and metabolic syndrome are related to various gallbladder diseases including gallbladder stones, cholecystitis, gallbladder polyps, and gallbladder cancers. We reviewed further literature on the obesity and gallbladder diseases, in aspects of epidemiology, mechanism, pathology and prevention.


Subject(s)
Body Mass Index , Cholecystitis/etiology , Exercise , Gallbladder Diseases/drug therapy , Gallbladder Neoplasms/epidemiology , Gallstones/epidemiology , Humans , Hyperinsulinism , Hypolipidemic Agents/therapeutic use , Insulin Resistance , Obesity/complications , Ursodeoxycholic Acid/therapeutic use , Weight Loss
15.
Article in Korean | WPRIM | ID: wpr-43462

ABSTRACT

Biliary cast describes the presence of casts within the biliary tree. It is resultant sequel of cholangitis and hepatocyte damage secondary to bile stasis and bile duct injury. Biliary cast syndrome was first reported in patient undergone liver transplantation. The pathogenesis of biliary cast is not clearly identified, but proposed etiologic factors include post-transplant bile duct damage, ischemia, biliary infection, or post-operative biliary drainage tube. Although biliary casts are uncommon, most of biliary cast syndrome are reported in the liver transplant or hepatic surgery patients. A few reports have been published about non-transplant or non-liver surgery biliary cast. We report two cases of biliary cast syndrome in non-liver surgery patients.


Subject(s)
Acute Disease , Ascariasis/diagnosis , Bile Duct Diseases/diagnosis , Bile Ducts/diagnostic imaging , Cholagogues and Choleretics/therapeutic use , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Female , Gallstones/diagnosis , Humans , Liver Cirrhosis, Biliary/diagnosis , Male , Middle Aged , Pancreatitis/etiology , Tomography, X-Ray Computed , Ursodeoxycholic Acid/therapeutic use
16.
Article in English | WPRIM | ID: wpr-35142

ABSTRACT

Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic liver disease of autoimmune etiology. The initial presentation of PBC is various from asymptomatic, abnormal liver biochemical tests to overt cirrhosis. The diagnosis of PBC is based on cholestatic biochemical liver tests, presence of antimitochondrial antibody and histologic findings of nonsuppurative destructive cholangitis. Although the diagnosis is straightforward, it could be underdiagnosed because of its asymptomatic presentation, or underrecognition of the disease. UDCA in a dose of 13-15 mg/kg is the widely approved therapy which can improve the prognosis of patients with PBC. However, one-third of patients does not respond to UDCA therapy and may require liver transplantation. Every effort to diagnose PBC in earlier stage and to develop new therapeutic drugs and clinical trials should be made.


Subject(s)
Autoantibodies/blood , Autoimmunity/immunology , Cholagogues and Choleretics/therapeutic use , Humans , Liver Cirrhosis, Biliary/diagnosis , Liver Transplantation , Ursodeoxycholic Acid/therapeutic use
17.
Gastroenterol. latinoam ; 21(2): 85-88, abr.-jun. 2010. tab, graf
Article in Spanish | LILACS | ID: lil-570003

ABSTRACT

El compromiso hepático es una rara manifestación de la infección por Mycoplasma pneumoniae. Casos de hepatitis colestásica sin compromiso pulmonar han sido descritos en niños con infección por M. pneumoniae, pero en adultos sólo unos pocos casos han sido reportados. En este artículo, presentamos el caso de un hombre de 21 años que consultó por un cuadro de fiebre, ictericia y dolor epigástrico asociado con alteración de los exámenes de laboratorio hepático. Los estudios serológicos de M. penumoniae fueron positivos para IgM e IgG. Los síntomas y exámenes de laboratorio mejoraron completamente luego del tratamiento con claritromicina y ácido ursodeoxicólico.


Liver dysfunction is an unusual manifestation of Mycoplasma pneumoniae infection. Cases of cholestatic hepatitis without pulmonary involvement have been described in children with M. pneumoniae infection,but only a few cases have been reported in adults. In this article, we report the case of a 21-year-old man who presented fever, jaundice and epigastric pain associated with altered liver function tests. Serological tests for M. pneumoniae were positive for IgG and IgM. Clinical symptoms and laboratory tests resolved completely after treatment with clarithromycin and ursodeoxicolic acid. A review of reported cases of liver involvement in M. pneumoniae infection is presented.


Subject(s)
Humans , Male , Adult , Cholestasis, Intrahepatic/microbiology , Hepatitis/microbiology , Mycoplasma pneumoniae/isolation & purification , Ursodeoxycholic Acid/therapeutic use , Clarithromycin/therapeutic use , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/drug therapy , Mycoplasma Infections/complications , Immunoglobulin G/analysis , Immunoglobulin M/analysis , Liver Function Tests , Mycoplasma pneumoniae/immunology
19.
Article in Korean | WPRIM | ID: wpr-14486

ABSTRACT

BACKGROUND/AIMS: This study investigated the clinical features and prognosis of primary biliary cirrhosis (PBC) in Korea. METHODS: Clinical data of patients diagnosed as PBC between 1997 and 2008 at eight referral hospitals were analyzed retrospectively. PBC was diagnosed based on liver function tests, presence of serum antimitochondrial antibody (AMA), and histopathological findings. RESULTS: In total, 251 patients (218 females, 33 males; mean age 54 years) were enrolled, and the mean follow-up duration was 33.5 months. At the diagnosis, 61% of the patients were asymptomatic, 12% had decompensated liver cirrhosis, and 98% were positive for AMA. The serum alkaline phosphate (ALP) level was 2.6 times the upper limit of normal, aspartate aminotransferase was 105 U/L, and bilirubin was 2.0 mg/dL. The mean Mayo risk score was 5.5, and the Child-Pugh class was A, B, and C in 79%, 19%, and 2% of the patients, respectively. Ursodeoxycholic acid (UDCA) was used for treatment in 88% of the patients, among which 70% exhibited biochemical responses defined as normalization or a >40% decrease in ALP at 6 months. Eight deaths occurred during the follow-up; the causes were variceal bleeding, hepatic failure, and sepsis. The overall 5-year survival rate was 95%. The poor prognostic factors were being older than 60 years, high bilirubin, low albumin, ascites, high Mayo risk score, Child-Pugh class C, and initial presence of hepatic decompensation. CONCLUSIONS: Most patients diagnosed as PBC were asymptomatic, and these patients had a favorable short-term prognosis. The prognosis of PBC was dependent on the initial severity of liver disease.


Subject(s)
Adult , Age Factors , Aged , Aged, 80 and over , Autoantibodies/metabolism , Bacterial Proteins/blood , Endopeptidases/blood , Female , Humans , Liver Cirrhosis, Biliary/diagnosis , Liver Function Tests , Male , Middle Aged , Prognosis , Republic of Korea , Retrospective Studies , Severity of Illness Index , Survival Rate , Ursodeoxycholic Acid/therapeutic use
20.
Rev. chil. pediatr ; 80(5): 459-466, oct. 2009. tab
Article in Spanish | LILACS | ID: lil-559580

ABSTRACT

Abstract: Familial Intrahepatic Cholestasis (FIC) includes a heterogeneous group of recessive autosomic alterations characterized by hepatocellular cholestasis secondary to the interruption of the normal process of synthesis of bilis. Objective: A description of FIC in 3 of 5 children of an index family. Clinical case: a 5 y.o. child with hepatosplenomegaly increased serum hepatic enzymes and biliary acids. Abdominal echography showed alterations compatible with hepatic fibrosis. Biopsy showed bridge fibrosis, duct proliferation, minimal chronic cholestasis. These findings were compatible with a phenotype FIC-3 with elevate levels of Gamma-glutamyl transferase. A mutation of MDR3 gene is responsible for the absence of biliary phospholipids, allowing a detergent effect of biliary acids upon the duct epithelium, developing cholangitis, fibrosis and later cirrhosis. Among four brothers, the mutation was found in two twin sisters. Three affected brothers were treated with ursodeoxicolic acid, 30 mg/Kg. Excellent results were obtained in the twin girls not in the index boy. The clinical expression of this illness is variable, and an elevation of aminotransferase must call attention to this possibility. Early diagnostic and treatment could avoid the development of hepatic damage and cirrhosis.


La Colestasia Intrahepática Familiar Progresiva (CIFP) comprende un grupo heterogéneo de alteraciones autosómicas recesiva caracterizadas por una colestasia hepatocelular secundaria a una interrupción del proceso normal de síntesis de la bilis. Objetivo: Describir la presentación de CIFP en 3 de 5 hijos de una familia estudiada. Caso clínico: Paciente de 5 a±os de edad (caso 1), que presenta una hepatoesplenomegalia, aumento de enzimas hepáticas y de ácidos biliares en suero. La ecotomografía abdominal describe alteraciones compatibles con fibrosis hepática. La biopsia reveló fibrosis en puente, proliferación ductular y colestasia crónica mínima. Estos hallazgos fueron compatibles con el fenotipo de una CIFP-3 con niveles elevados de Gamaglutamiltransferasa (GGT). Una mutación del gen MDR3 es responsable de la ausencia de fosfolípidos en la bilis, lo que permite la acción detergente de los ácidos biliares sobre el epitelio de los conductos desencadenando una colangitis, fibrosis y luego cirrosis. De los cuatro hermanos del caso 1 se detectó la enfermedad en 2 hermanas gemelas (casos 2 y 3). Estos tres niños afectados fueron tratados con ácido ursodeoxicólico 30 mg/kilo/peso, logrando excelentes resultados en las gemelas pero no en el caso 1. Conclusión: Se presenta a 3 hermanos con el fenotipo de CIFP. La expresión clínica de esta enfermedad puede ser variable y de manifestación tardía, la elevación de las aminotransferasas debe considerar esta patología en el diagnóstico diferencial de las numerosas causas que dan origen a un aumento de estas enzimas. Sólo el diagnóstico y tratamiento precoz puede evitar la evolución a un daño hepático irreversible como es la cirrosis.


Subject(s)
Humans , Male , Female , Child , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/genetics , Cholestasis, Intrahepatic/drug therapy , Siblings , Ursodeoxycholic Acid/therapeutic use , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Cholagogues and Choleretics/therapeutic use , Cholestasis, Intrahepatic/blood , Family , Mutation , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP-Binding Cassette Transporters/genetics , gamma-Glutamyltransferase/blood
SELECTION OF CITATIONS
SEARCH DETAIL